ISSCR Innovation Showcase: Optimized, Serum-Free, In Vitro Culture Conditions for CRISPR-Mediated Genome Editing of CD34+ Cells
In this Innovation Showcase talk from ISSCR 2020 Virtual, Amanda Fentiman, Hematology Product Manager, gives a detailed overview of CRISPR-mediated genome editing of CD34+ cells in optimized, serum-free, in vitro culture conditions.
In this Innovation Showcase talk from ISSCR 2020 Virtual, Amanda Fentiman, Hematology Product Manager, gives a detailed overview of CRISPR-mediated genome editing of CD34+ cells in optimized, serum-free, in vitro culture conditions.
The ability to genetically manipulate hematopoietic stem and progenitor cells (HSPCs) can facilitate gains in our understanding of the mechanisms that regulate hematopoiesis and contribute to the development of novel cellular therapies. Optimal culture conditions are key to maintaining the viability, proliferation and differentiation potential of HSPCs and achieve high editing efficiencies in genome editing experiments. In this presentation, Amanda discusses STEMCELL’s products for in vitro expansion of primary human hematopoietic cells, including primitive stem and progenitor cell populations. She also outlines an optimized protocol for gene editing of cord blood-derived CD34+ cells and discusses STEMCELL’s new cGMP animal component-free StemSpan™ medium, manufactured to relevant 21 CFR Part 820 guidelines.
As a supporter of, and participant in, ISSCR’s 2020 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2020.
This presentation does not represent an endorsement from or support of the ISSCR.
The ability to genetically manipulate hematopoietic stem and progenitor cells (HSPCs) can facilitate gains in our understanding of the mechanisms that regulate hematopoiesis and contribute to the development of novel cellular therapies. Optimal culture conditions are key to maintaining the viability, proliferation and differentiation potential of HSPCs and achieve high editing efficiencies in genome editing experiments. In this presentation, Amanda discusses STEMCELL’s products for in vitro expansion of primary human hematopoietic cells, including primitive stem and progenitor cell populations. She also outlines an optimized protocol for gene editing of cord blood-derived CD34+ cells and discusses STEMCELL’s new cGMP animal component-free StemSpan™ medium, manufactured to relevant 21 CFR Part 820 guidelines.
As a supporter of, and participant in, ISSCR’s 2020 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2020.
This presentation does not represent an endorsement from or support of the ISSCR.
Publish Date:
August 17, 2020
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
ISSCR Innovation Showcase: Advanced Brain Organoid Co-Culture Systems
Publish Date: August 17, 2020
Explore Our Products
-
cGMP medium, for culture and expansion of human hematopoietic cells
